Growth Drivers Valeant is a multinational specialty pharmaceutical company engaged in the development, manufacture, and marketing of various pharmaceutical products, particularly in the areas of neurology, dermatology and branded generics. The company aims to expand its business through acquisitions. This year Valeant has acquired Bausch+Lomb in Aug 2013, Obagi Medical Products, Inc. in Apr 2013, some assets of Eisai Inc. in Feb 2013 and Natur Produkt International also in Feb 2013. Valeant acquired Bausch+Lomb to strengthen its ophthalmology portfolio. The acquisition will enable Valeant to penetrate into the growing eye health market fueled by an aging patient population, an increased rate of diabetes, and increasing demand from the emerging markets. Last month, Valeant entered into a definitive agreement to acquire all of the outstanding common stock of Solta Medical, Inc. ( SLTM ) for $2.92 per share in cash or $250 million.